Reslizumab

Phase 3

Teva Pharmaceutical Industries Limited (TEVA)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Eosinophilic Asthma

View Full Landscape

Drug Information

Target Indication

Eosinophilic Asthma

Clinical Trial

NCT01270464

Last updated: 1/22/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA8/15/2016

Cinqaero

Cinqaero is indicated as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

TEVA

Teva Pharmaceutical Industries Limited

Pharmaceutical Preparations•North America•NYSE

Related Pipeline

Budesonide/Formoterol SPIROMAX®Phase 3

Asthma

Albuterol SulfatePhase 3

Asthma

Fluticasone Propionate/SalmeterolPhase 3

Asthma

AlbuterolPhase 3

Asthma

DeutetrabenazinePhase 3

Huntington Disease

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts